Palbace® (palbociclib)

Palbace®  Indications

Palbociclib is a kinase inhibitor indicated in a combination with Letrozole for the treatment of postmenopausal women with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. Palbociclib is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative advanced or metastatic breast cancer in the combination with fulvestrant in women with disease progression following endocrine therapy.1

Changing the outlook in metastatic breast cancer (mBC)

PALBACE is the first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for HR+/HER2- locally advanced and metastatic breast cancer.1,2 

As a 1st line therapy in HR+/HER2- locally advanced and metastatic breast cancer, PALBACE with letrozole has demonstrated >2 years mPFS vs letrozole alone in the PALOMA-2 study.

In PALOMA-3, PALBACE plus fulvestrant, in endocrine resistant cases, have delivered more than double the mPFS compared with fulvestrant monotherapy, 11.2 months with PALBACE plus fulvestrant vs. 4.6 months with fulvestrant plus placebo.4,5 

References:
1. Palbace (Palbociclib) Local Prescribing Document. Pfizer Products India Private Limited. Version 8.0, LPDPAB112018.
2. Kim ES, et al. Target Oncol. 2017;12(3):373-383.
3. Rugo HS, et al. Breast Cancer Res Treat. 2019 Jan 10. [Epub ahead of print]
4. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-39.
5. Turner NC, et al. N Engl J Med. 2018 Nov 15;379(20):1926-1936.

PP-IBR-IND-0140. 19-08-2019
Please click on Prescribing Information link to view safety and adverse events information of Palbace.
For the use only of registered medical practitioner, or a hospital or a laboratory.